載入...
Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury
A screen by Kost-Alimova et al.(1) suggests that the FDA-approved SYK inhibitor fostamatinib inhibits MUC1 in the respiratory tract and has the potential to treat serious outcomes of coronavirus COVID-19, including acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).
Na minha lista:
| 發表在: | Cell Rep Med |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Elsevier
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7670931/ https://ncbi.nlm.nih.gov/pubmed/33225317 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.xcrm.2020.100145 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|